Virology News

The development of a vaccine able to prevent infection or severe disease course of SARS-CoV-2 is a priority to stem the current COVID-19 pandemic and to be better prepared for future flare-ups. To accelerate T-cell immunogen design, many current approaches are employing epitope prediction strategies. Although such approaches have great merit, it is also important that unbiased approaches to characterizing the T-cell response to SARS-CoV-2 are incorporated into vaccine design, in order to generate a comprehensive picture of the total virus-specific T-cell response and to define correlates of protective immunity against the virus. Ever since the first identification of binding motifs for T-cell antigens presented by HLA class I molecules by Rammensee and colleagues almost 30 years ago, epitope identification has been greatly facilitated by epitope prediction algorithms [1]. Over the years, many vaccines designs targeting infectious pathogens as well as cancer neoantigens have been based on in silico prediction of potential HLA class I–restricted epitopes, and a series of vaccine candidates that apply such strategies to SARS-CoV-2 are currently in development. However, even though numerous prediction algorithms have been developed and gradually improved, there are several considerations that may threaten or limit the success of such approaches. Epitope length is highly variable and not properly captured by prediction algorithms Although the initial characterization of eluted HLA class I epitopes by the Rammensee lab in 1991 produced predominantly 9-mer epitopes, there was already the notion of longer and shorter sequences that can be bound and effectively presented by HLA class I molecules [1]. 

Climate Change, Economy & Trade, Featured, Financial Crisis, Global, Headlines, Health, Humanitarian Emergencies, Labour, Multimedia, Podcast, TerraViva United Nations OPINION COVID19 and Its Impact on Pacific Island States By William W. Ellis Reprint | | Print | TORONTO, May 29 2020 (IPS) - By now, the impact of COVID19 on our daily lives has been well documented, especially in advanced economies. Anxiety about the future continues to grow everywhere. Much of the corporate news coverage we consume has focused on the toll this pandemic will take on mainland countries. Often neglected, however, is the unique position Pacific Island States find themselves in. Globally, there are close to 6 million confirmed cases of COVID19. According to the Pacific Community (SPC), there are 292 cases of the virus across its membership – a truly small number, considering Papua New Guinea’s population of 8.6 million people. 

According to this latest study, the 2020 growth of Swine Circovirus Vaccine will have significant change from previous year. By the most conservative estimates of global Swine Circovirus Vaccine market size (most likely outcome) will be a year-over-year revenue growth rate of XX% in 2020, from US$ xx million in 2019. We give this scenario a XX% probability, where under the scenario the supply chain will start to recover and quarantines and travel bans will ease, over the Q2. Longer-term, the effect of COVID-19 will be felt throughout the year with some degree of harm done by the virus. Over the next five years the Swine Circovirus Vaccine market will register a XX% CAGR in terms of revenue, the global market size will reach US$ XX million by 2025.                            Many companies are operating in the market and conduct their businesses through joint ventures, which benefit the overall market. The Key Players Analysis for the industry is presented in chapter 12 of this report.   This study specially analyses the impact of Covid-19 outbreak on the Swine Circovirus Vaccine, covering the supply chain analysis, impact assessment to the Swine Circovirus Vaccine market size growth rate in several scenarios, and the measures to be undertaken by Swine Circovirus Vaccine companies in response to the COVID-19 epidemic.                       Top Manufactures in Global Swine Circovirus Vaccine Market Includes: Chopper Biology Merial ChengDu Tecbond Qilu Animal DHN Ringpu Biology Jinyu Bio-Technology CAVAC Zoetis Komipharm   Market Segment by Type, covers: Genetic Engineering Vaccine Killed Vaccines   Market Segment by Applications, can be divided into: Piglets Adults Pigs   In addition, this report discusses the key drivers influencing market growth, opportunities, the challenges and the risks faced by key manufacturers and the market as a whole. It also analyzes key emerging trends and their impact on present and future development.